AC
ZSAN

Armistice Capital’s Zosano Pharma Corporation ZSAN Stock Holding History

Armistice Capital’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,714
Closed -$936K – 59
2016
Q4 		$936K Buy
1,714
+517
+43% +$255K 0.22% 47
2016
Q3 		$662K Buy
+1,197
New +$954K 0.21% 43

Other funds holding ZSAN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Armistice Capital's ZSAN Position: Q1 2017 in Review

Armistice Capital sold out of Zosano Pharma Corporation (ZSAN) in Q1 2017, closing a stake of 1,714 shares — an estimated $936K sold.

Armistice Capital first reported a position in ZSAN in Q3 2016 and held it in 2 quarters. The position peaked at $936K in Q4 2016. 26 funds tracked by Wall St. Rank hold ZSAN as of Q1 2017.

  • Armistice Capital reported no remaining Zosano Pharma Corporation position as of Q1 2017 after selling out during the quarter.
  • Armistice Capital sold 1,714 Zosano Pharma Corporation shares in Q1 2017, an estimated $936K.
  • Armistice Capital first reported a position in Zosano Pharma Corporation in Q3 2016 and held it in 2 quarters.
  • Armistice Capital's Zosano Pharma Corporation position peaked at $936K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2017.

Based on Armistice Capital's 13F filing for Q1 2017, filed 15 May 2017.